相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Evidence for a macromolecular complex in poor prognosis CLL that contains CD38, CD49d, CD44 and MMP-9
Andrea G. S. Buggins et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Rituximab inhibits B-cell receptor signaling
Samar Kheirallah et al.
BLOOD (2010)
Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia
Maike Buchner et al.
BLOOD (2010)
The microenvironment differentially impairs passive and active immunotherapy in chronic lymphocytic leukaemia-CXCR4 antagonists as potential adjuvants for monoclonal antibodies
Maike Buchner et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Rituximab Maintenance Treatment of Relapsed/Resistant Follicular Non-Hodgkin's Lymphoma: Long-Term Outcome of the EORTC 20981 Phase III Randomized Intergroup Study
Marinus H. J. van Oers et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Antigenic Modulation and Rituximab Resistance
Ronald P. Taylor et al.
SEMINARS IN HEMATOLOGY (2010)
Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML
Zhihong Zeng et al.
BLOOD (2009)
The microenvironment in mature B-cell malignancies: a target for new treatment strategies
Jan A. Burger et al.
BLOOD (2009)
Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting
Antonina V. Kurtova et al.
BLOOD (2009)
CD38/CD31, the CCL3 and CCL4 Chemokines, and CD49d/Vascular Cell Adhesion Molecule-1 Are Interchained by Sequential Events Sustaining Chronic Lymphocytic Leukemia Cell Survival
Antonella Zucchetto et al.
CANCER RESEARCH (2009)
Curcumin Inhibits Prosurvival Pathways in Chronic Lymphocytic Leukemia B Cells and May Overcome Their Stromal Protection in Combination with EGCG
Asish K. Ghosh et al.
CLINICAL CANCER RESEARCH (2009)
Rituximab-Mediated Cell Signaling and Chemo/Immuno-sensitization of Drug-Resistant B-NHL Is Independent of Its Fc Functions
Mario I. Vega et al.
CLINICAL CANCER RESEARCH (2009)
The role of natalizumab in hematopoietic stem cell mobilization
Frank Neumann et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2009)
CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential
Tait D. Shanafelt et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study
Alejandro Martin et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2008)
CD49d expression is an independent risk factor of progressive disease in early stage chronic lymphocytic leukemia
Davide Rossi et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2008)
Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis
M. Krumbholz et al.
NEUROLOGY (2008)
Stromal Gene Signatures in Large-B-Cell Lymphomas
G. Lenz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
CD38 at the junction between prognostic marker and therapeutic target
Silvia Deaglio et al.
TRENDS IN MOLECULAR MEDICINE (2008)
Bone marrow stromal cells prevent apoptosis of lymphoma cells by upregulation of anti-apoptotic proteins associated with activation of NF-κB (RelB/p52) in non-Hodgkin's lymphoma cells
T. Lwin et al.
LEUKEMIA (2007)
Bone biopsy derived marrow stromal elements rescue chronic lymphocytic leukemia B-cells from spontaneous and drug induced cell death and facilitates an angiogenic switch
Neil E. Kay et al.
LEUKEMIA RESEARCH (2007)
Natalizumab for multiple sclerosis
Richard M. Ransohoff
NEW ENGLAND JOURNAL OF MEDICINE (2007)
'Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions'
B. Bonavida
ONCOGENE (2007)
Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias
Zhihong Zeng et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells
M Burger et al.
BLOOD (2005)
Anti-α4 integrin therapy for multiple sclerosis -: Mechanisms and rationale
GPA Rice et al.
NEUROLOGY (2005)
Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells
SS Dave et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance
MR Smith
ONCOGENE (2003)
Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia
T Matsunaga et al.
NATURE MEDICINE (2003)
Integrin-dependence of lymphocyte entry into the splenic white pulp
CG Lo et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Natalizumab for active Crohn's disease.
S Ghosh et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Drug resistance and drug development in multiple myeloma
WS Dalton
SEMINARS IN ONCOLOGY (2002)
CD20-mediated apoptosis: signalling through lipid rafts
JP Deans et al.
IMMUNOLOGY (2002)
Gene expression profiling of the functionally distinct human bone marrow stromal cell lines HS-5 and HS-27a
L Graf et al.
BLOOD (2002)
The chemokine receptor CCR7 and α4 integrin are important for migration of chronic lymphocytic leukemia cells into lymph nodes
KJ Till et al.
BLOOD (2002)
Role of integrins in cell invasion and migration
JD Hood et al.
NATURE REVIEWS CANCER (2002)
Survival of B lineage leukemic cells: Signals from the bone marrow microenvironment
LF Gibson
LEUKEMIA & LYMPHOMA (2002)
The affinity of integrin α4β1 governs lymphocyte migration
DM Rose et al.
JOURNAL OF IMMUNOLOGY (2001)
VLA-4 mediated adhesion to bone marrow stromal cells confers chemoresistance to adherent lymphoma cells
CD Weekes et al.
LEUKEMIA & LYMPHOMA (2001)
Rheumatoid arthritis synovial stromal cells inhibit apoptosis and up-regulate Bcl-xL expression by B cells in a CD49/CD29-CD106-dependent mechanism
K Hayashida et al.
JOURNAL OF IMMUNOLOGY (2000)
Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells
DM Shan et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2000)
分享论文
